Reports summarize these findings in a structured, easy-to-read format, including risk stratification percentiles—helping guide lifestyle and preventative care discussions. All results are generated directly from a routine chest CT, such as those done for lung cancer screening, without the need for additional imaging.
CAC™ brings actionable cardiovascular risk data into the workup of patients with breathlessness, expediting diagnosis and guiding referrals.For radiologists, it provides objective, reproducible quantification, 3D visualization, and artery-specific scoring to ensure comprehensive and efficient interpretation. The result is amore confident, timely distinction between cardiac and pulmonary causes of dyspnea, with higher diagnostic accuracy and better outcomes for patients.
With CAC, you have a powerful, FDA-cleared tool for fullyautomated detection, visualization,and quantification ofcoronary artery disease—enabling faster, more thorough carefrom a single scan.
Imbio, a fully owned subsidiary of 4DMedical, is the legal manufacturer of CAC
